Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 25% during trading on Friday . The stock traded as high as C$0.36 and last traded at C$0.35. Approximately 1,444,856 shares were traded during mid-day trading, an increase of 111% from the average daily volume of 684,559 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 25.0 %
The stock has a market capitalization of C$30.49 million, a P/E ratio of -17.50 and a beta of 0.20. The stock’s 50 day moving average price is C$0.12 and its 200-day moving average price is C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Short Selling – The Pros and Cons
- Abbott Laboratories Will Outperform Healthcare Stocks in 2025
- Market Cap Calculator: How to Calculate Market Cap
- PepsiCo: 53 Years of Dividend Growth and Still Going Strong
- Investing in Travel Stocks Benefits
- Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
